Catalyst Pharmaceuticals Operating Income Over Time
| CPRX Stock | USD 25.00 0.70 2.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Catalyst Pharmaceuticals Performance and Catalyst Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. Projected growth potential of Catalyst fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Catalyst Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.2 | Earnings Share 1.71 | Revenue Per Share | Quarterly Revenue Growth 0.153 | Return On Assets |
Understanding Catalyst Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Catalyst's accounting equity. The concept of intrinsic value—what Catalyst Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Catalyst Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Catalyst Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Catalyst Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Catalyst Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Catalyst Pharmaceuticals and related stocks such as Mineralys Therapeutics, Cidara Therapeutics, and Apellis Pharmaceuticals Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MLYS | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (18.7 M) | (31.5 M) | (84.7 M) | (192.4 M) | (173.2 M) | (164.5 M) |
| CDTX | (792 K) | (792 K) | (792 K) | (1.1 M) | (11.6 M) | (32.3 M) | (48.4 M) | (55.7 M) | (63.3 M) | (41.7 M) | (71.8 M) | (42.3 M) | (29.7 M) | (27.1 M) | (176.1 M) | (158.5 M) | (150.6 M) |
| APLS | (4 M) | (4 M) | (4 M) | (4 M) | (11.3 M) | (46.6 M) | (27.3 M) | (50.8 M) | (127.9 M) | (288 M) | (213.7 M) | (536.3 M) | (594.6 M) | (517.1 M) | (165 M) | (148.5 M) | (155.9 M) |
| BEAM | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (45.7 M) | (75.2 M) | (132.8 M) | (392.5 M) | (338.5 M) | (176.5 M) | (415.6 M) | (374 M) | (355.3 M) |
| ADPT | (44.5 M) | (44.5 M) | (44.5 M) | (44.5 M) | (44.5 M) | (44.5 M) | (44.5 M) | (44.5 M) | (49.8 M) | (78.4 M) | (152.8 M) | (209 M) | (200.2 M) | (227 M) | (162.5 M) | (146.3 M) | (153.6 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (50.7 M) | (54.5 M) | (86.9 M) | (129.9 M) | (134.4 M) | (171.3 M) | (252.1 M) | (226.8 M) | (215.5 M) |
| IDYA | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (36.4 M) | (44.3 M) | (35.3 M) | (50.3 M) | (62.5 M) | (134.4 M) | (327 M) | (294.3 M) | (279.6 M) |
| RXRX | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (62.4 M) | (84.6 M) | (182.8 M) | (245.7 M) | (350.1 M) | (479 M) | (431.1 M) | (409.5 M) |
| KNSA | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (65.4 M) | (108.2 M) | (170 M) | (157.4 M) | (156.6 M) | 9.8 M | (25.2 M) | (45.6 M) | (52.5 M) | (55.1 M) |
| AGIO | (16.6 M) | (16.6 M) | (23 M) | (38.9 M) | (54.1 M) | (118.7 M) | (201 M) | (320.8 M) | (362.5 M) | (426.3 M) | (335.9 M) | (378.4 M) | (389 M) | (391.5 M) | (425.7 M) | (383.2 M) | (402.3 M) |
Catalyst Pharmaceuticals and related stocks such as Mineralys Therapeutics, Cidara Therapeutics, and Apellis Pharmaceuticals Operating Income description
Operating Income is the amount of profit realized from Catalyst Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Catalyst Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Catalyst Pharmaceuticals | CPRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 355 Alhambra Circle, |
| Exchange | NASDAQ Exchange |
USD 25.0
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.